Antiviral drugs that act directly on hepatitis C virus (HCV) have high cure rates and are well tolerated. Short courses of these drugs not only improve patient compliance, but also reduce the financial burden on patients. Currently, the efficacy of 8 weeks of Ledipasvir (LDV) + Sofosbuvir (SOF) + Ribavirin is good, but the efficacy of 6 weeks is not so good. Can LDV and SOF be combined with other direct-acting antivirals to shorten the duration of treatment for hepatitis C? Professor Kohli and others from the NIH studied this and conducted a phase 2A clinical trial. They found that a triple combination of LDV and SOF in combination with other drugs could reduce the duration of treatment for hepatitis C to 6 weeks. The results of the study were published last month in the journal JAMA. The study included 60 untreated patients with HCV type 1 infection in three groups: SOF+LDV for 12 weeks, SOF+LDV+GS-9669 for 6 weeks, and SOF+LDV+GS-9451 for 6 weeks. The primary endpoint event of the study was the proportion of patients with a sustained virologic response (SVR12) at 12 weeks after completion of treatment, which was evaluated as a serum HCV RNA concentration of less than 43 IU/mL (the lower limit of quantitative detection). The study found that: 1. All patients in the 12-week SOF+LDV treatment group achieved SVR12. 2. 19 patients in the 6-week SOF+LDV+GS-9669 treatment group achieved SVR12 (one patient relapsed 2 weeks after the end of treatment). 3. 19 patients treated with SOF+LDV+GS-9451 for 6 weeks achieved SVR12 (one patient was lost to follow-up after 4 weeks of sustained viral response). This study found that both triple regimens were well tolerated with high cure rates for HCV. In HCV type 1-infected patients without cirrhosis, these two triple drug regimens shortened the duration of treatment to achieve sustained virologic response.